Home » Stock Symbols » AZN.L

AstraZeneca plc

AZN.L: Share Price & Live Data

6 GBP
-348.00 (-4.87%)
Price open 7,000.00
Previous close 7,142.00
Market cap 89.15B
Volume 4.47M
Day high 7,142.00
Day low 6,689.00
Year high 8,227.88
Year low 5,626.00

About AstraZeneca plc

AstraZeneca is a multinational that operates as a pharmaceutical and biopharmaceutical company. The company’s roots date back to 1913 when it was founded as Astra AB by 400 doctors in Sweden. In 1999, Astra AB merged with British Zeneca Group resulting in the formation of AstraZeneca

Headquartered in Cambridge, United Kingdom, the company is engaged in the development and commercialization of medicines. The company focuses on oncology cardiovascular, respiratory treatments, among others. Some of its leads products include Tagrisso and Nolvadex.

Just like other giant pharmaceuticals, it has grown through acquisitions. Its notable acquisitions include Spurge for $440 million and Bristol Myers Squibb for $3.4 billion. In 2017, the company rejected a $117 billion takeover bid by Pfizer. A merger of the two would have resulted in the world’s biggest drugmaker.

The pharmaceutical company is currently listed in the New York Stock Exchange as well as the London Stock Exchange and OMX Exchange.

Latest AstraZeneca plc News

AstraZeneca expects a $100 million drop in Q4 profits following discontinuation of Epanova drug

On Monday, AstraZeneca, a biopharmaceutical company devoted to research and development of innovative drugs, revealed that it will soon discontinue Epanova, a heart disease drug to be used by people suffering from mixed dyslipidemia. The testing for the drug will be halted in its late-stage trial resulting in a drop of around $100 million...

FTSE 100 Index – A brief overview of Thursday, October 24th, 2019

In the recent news, the FTSE 100 index has been observed trading higher than expected this morning, Thursday, October 24th, 2019. While the Brexit uncertainty was expected to keep the financial markets under pressure until the decision from the European Union regarding UK’s request for an extension wasn’t announced, the market opened at 7...

AstraZeneca share price down despite upbeat trial results

AstraZeneca’s share price (LON:AZN) has fallen into the red this morning even as the blue-chip group posted upbeat results from a trial evaluating its oncology treatment Lynparza. The update follows the Anglo-Swedish group’s recent first-quarter results which saw the company disclose that it had  benefitted from its new medicines which he...

AstraZeneca share price: Deutsche Bank remains bullish on pharmco

Deutsche Bank continues to see AstraZeneca (LON:AZN) as a ‘buy,’ pointing to the pharmco’s ‘strong start’ to the year, Sharecast reports. The comments came after the Anglo-Swedish drugmaker updated investors on its first-quarter performance last week, posting a rise in sales, having benefitting from its new treatments. AstraZeneca’s share...

AstraZeneca share price subdued despite rise in Q1 sales

Shares in AstraZeneca (LON:AZN) have slipped into the red in London in today’s session, even as the blue-chip drugmaker posted a rise in sales for the first three months of the year. The Anglo-Swedish pharmco disclosed that it had benefitted from its new medicines which helped offset a decline in older drugs which have been facing competi...

AstraZeneca share price outperforms as heart drug meets goal in late-stage trial

Brilinta reduces cardiovascular events in patients with coronary artery disease and type-2 diabetes

Overview

Name
AstraZeneca plc
Exchange
London Stock Exchange
Sector
Healthcare
Industry
Drug Manufacturers—General
Country
United Kingdom
Full time employees
0

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.